January 27, 2023 | Issue #35

Happy Friday. This week, we took a break from our weekly newswire to FINALLY get you our new report that we've been working on since the turn of the new year. Continue scrolling for the link and to learn more.As always, thank you for your support! 🙌

Introducing... The 2022 Longevity Funding Report

We are proud to announce the release of our inaugural Longevity Funding Report, for the year 2022.To help readers better understand today’s nascent longevity venture market, we’ve compiled all the fundraising data we independently collected for longevity-related companies in 2022.Ultimately, this market research report aims to provide a bird’s eye view of the emerging ecosystem of longevity-related startups focused on various aging interventions, drug discovery and development, clinical research, disease prevention, and age-defying technology.

What's more?

To get ahead of it, there's a good chance that other "Longevity Funding" reports may circulate in the coming weeks... all with different figures than ours. Now, how much of a discrepancy will there be?

We don't know...

But what we

do

know is that we dedicated hours to vet each and every raise, ensuring our report best represents the longevity venture market. And although defining 'longevity' is complex, we are confident that our report is the closest approximation of this new and emerging market. Additionally, the report prioritizes

only private longevity-related companies with proof of raise

. Therefore, we have excluded all public stock offerings, grants, and debt financings.

Again, to access the report, just

click here

.

*Performance:

Latest Price: $127.947d-Return: 3.94% Market Cap: $13.11b

*Big Movers:Tenaya (TNYA): 22.35%Vaxxinity (VAXX): 22.00%Clene (CLNN): -18.75%

*Numbers are based on yesterday's close. Big Movers show past 7d performance.